Shionogi Pharma, Inc. Sustainability Profile
Shionogi Pharma, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and operates extensively across North America. Founded in 1878, Shionogi has established itself as a leader in developing innovative therapies, particularly in the fields of infectious diseases, pain management, and central nervous system disorders. The company is renowned for its unique approach to drug development, focusing on both prescription medications and over-the-counter products that address unmet medical needs. Notable achievements include the successful launch of several key therapies that have significantly improved patient outcomes. With a commitment to research and development, Shionogi Pharma continues to strengthen its market position, contributing to advancements in healthcare and enhancing the quality of life for patients worldwide.
DitchCarbon Score
How does Shionogi Pharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shionogi Pharma, Inc.'s score of 67 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shionogi Pharma, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Shionogi & Co., Ltd., which may influence its climate commitments and emissions reporting. As part of its corporate family, Shionogi Pharma, Inc. inherits climate initiatives and targets from Shionogi & Co., Ltd. However, there are no documented reduction targets or specific climate pledges available for Shionogi Pharma, Inc. at this time. The absence of emissions data and reduction initiatives suggests that the company may still be in the process of establishing its own climate strategy or reporting framework. In the broader context, Shionogi & Co., Ltd. is likely to have its own sustainability goals and emissions reduction strategies, which may indirectly impact Shionogi Pharma, Inc. as it aligns with the parent company's objectives. As the company develops its climate commitments, it will be essential to monitor any future announcements regarding emissions data and reduction targets.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 43,456,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 46,681,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 196,761,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Shionogi Pharma, Inc.'s Industry?
How Carbon Intensive is Shionogi Pharma, Inc.'s Location?
Shionogi Pharma, Inc.'s Scope 3 Categories Breakdown
Shionogi Pharma, Inc.'s Scope 3 emissions, which increased by 1% last year and decreased by approximately 27% since 2017, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 66% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 57% of Scope 3 emissions.
Top Scope 3 Categories
Shionogi Pharma, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Shionogi Pharma, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
